SCHEMBL5353454

SCHEMBL5353454

COc1cc2c(=O)c(-c3noc(Cc4ccccc4)n3)cn(Cc3ccc(Cl)cc3)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MAPK1 P28482 3/20 0.52
TSHR P16473 2/20 0.52
MEN1 O00255 2/20 0.52
LMNA P02545 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPT P10636 6/20 0.52
TP53 P04637 3/20 0.52
SMN1; SMN2 Q16637 5/20 0.47
POLB P06746 1/20 0.47
ALOX15 P16050 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
NTSR1 P30989 1/20 0.44
GPR55 Q9Y2T6 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357868 0.93 MAPK1 (0.52) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5344829 0.89 MAPT (0.45) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5353654 0.89 LMNA (0.55) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5346943 0.88 KMT2A (0.47) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL14386939 0.84 KMT2A (0.43) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5361237 0.84 ALDH1A1 (0.52) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5464650 0.84 SMN1; SMN2 (0.45) KMT2AMAPK1LMNAMAPTSMN1; SMN2
SCHEMBL5370074 0.84 TP53 (0.45) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5356153 0.83 TP53 (0.44) KMT2AMAPK1TSHRMEN1LMNA
SCHEMBL5354226 0.82 MAPT (0.45) KMT2AMEN1LMNAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 KMT2A 4280/4885MAPK1 4356/4885TSHR 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.